Retrophin Announces Pricing of Public Offering of Common Shares
Uplisted to NASDAQ Global Market Under Symbol RTRX
NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (RTRX)(formerly OTCQB:RTRX) today announced the pricing of an underwritten public offering of 4,705,882 shares of its common stock, offered at a price of $8.50 per share. The gross proceeds from this offering, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $40,000,000. The offering is expected to close on or about January 15, 2014, subject to customary closing conditions. Retrophin also granted the underwriter a 30-day option to purchase 705,882 additional shares of its common stock.
In connection with this offering, the Company received approval to list its common stock on the NASDAQ Global Market under the ticker symbol RTRX.
All of the shares sold in the offering are being sold by Retrophin, with the proceeds to be used to obtain regulatory approval for the reintroduction of Syntocinon into the US market for aiding milk letdown, to initiate clinical trials of Retrophins product candidates, including Syntocinon for the treatment of Schizophrenia and Autism Spectrum Disorders, RE-034 for the treatment of Infantile Spasms and Nephrotic Syndrome, RE-024 for the treatment of Pantothenate Kinase Associated Neurodegeneration, and sparsentan for the treatment of Focal Segmental Glomerulosclerosis. Any remaining net proceeds will be used for the further advancement of Retrophins early stage development programs, for further product development and for general corporate purposes.
Jefferies LLC is acting as sole book-running manager for the offering. Roth Capital Partners, Ladenburg Thalmann & Co. Inc. and Summer Street Research Partners are acting as co-managers.
A registration statement relating to the shares of Retrophin common stock being offered has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC (SCUR)"). A prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the prospectus, when available, may be obtained from Jefferies LLC, Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's pipeline includes compounds for several catastrophic diseases, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's filings with the Securities and Exchange Commission.
Marc Panoff, CFO
Source: Retrophin, Inc.Copyright Business Wire 2014